IJCRR - 5(6), March, 2013
HOMOCYSTEINE, C-REACTIVE PROTEIN AND TRADITIONAL CARDIOVASCULAR RISK MARKERS IN POLYCYSTIC OVARY SYNDROME
Author: Seerla Lalitha Devi, Syed Abdul Jaweed
Objectives: Polycystic ovary syndrome one of the major Endocrine and reproductive abnormality which represent the largest unique young women at high risk for development of premature atherosclerotic heart disease. The Metabolic disturbances associated with PCOS like Insulin resistance, hyperandrogenism, and hypertension may adversely accelerate the cardiovascular risk profile in these young Women. With this background, a case control study was undertaken to evaluate the levels of Traditional and Novel CV risk markers in PCOS women compared to healthy controls. Methods: Fasting blood Glucose, Insulin, Insulin resistance (homeostasis model assessment, HOMA-IR), Testosterone, Lipid levels, Homocysteine, C- reactive protein and Uric acid levels were determined in Fourty diagnosed PCOS women and healthy age matched controls. All biochemical analysis was done using commercial enzymatic kits. Results: Testosterone the main component of PCOS, HOMA-IR were significantly (p<0.05) higher in PCOS women than controls. Insulin, Total cholesterol, TGL, HDL, LDL levels were also significantly (p<0.05) higher in PCOS women and the Novel CV markers Homocysteine, CRP, Uric acid were significantly (p<0.05) elevated in PCOS women compared to controls. Conclusion: Both Traditional and Novel CV risk markers were significantly elevated in PCOS women indicating early onset cardiovascular risk in these young women. Hence, correction and routine screening for these parameters helps in early identification of cardiovascular risk and can prevent the development of endothelial dysfunction, which is a reversible early event in atherosclerosis and appropriate treatment should be aimed to control these parameters.
Keywords: Insulin resistance, Dyslipidemia, Endothelial dysfunction, Cardiovascular risk
Seerla Lalitha Devi, Syed Abdul Jaweed. HOMOCYSTEINE, C-REACTIVE PROTEIN AND TRADITIONAL CARDIOVASCULAR RISK MARKERS IN POLYCYSTIC OVARY SYNDROME International Journal of Current Research and Review. 5(6), March, 59-68
1. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Clin Obstet Gynaecol. 2004; 18 : 671-683.
2. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol 2002; 174: 1-5.
3. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286-288.
4. Taponen S, Martikainen H, Jarvelin MR, et al. Metabolic cardiovascular disease risk factors in women with self reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. Clin Endocrinol Metab 2004; 89: 2114-2118.
5. Eleni Kousta, George Tolis, Stephen Franks. Polycystic ovary syndrome. Revised diagnostic criteria and long-term health consequences Hormones 2005; 4(3):133-147.
6. Blake GJ, Ridker PM. Inflammatory biomarkers and cardiovascular risk prediction. J Intern Med 2002; 252:283–94.
7. Bickerton A S T, Clark N, Meeking D, Shaw K M, Crook M, Lumb P, et al. Cardiovascular risk in women with polycystic ovarian syndrome. J Clin Pathol 2005; 58:151–154.
8. Manuel Luque-Rami´rez, Francisco A lvarezBlasco, Miguel Giovanni Uriol Riveraand He´ctor F. Escobar-Morreal. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinylestradiol plus cyproterone acetate versus metformin. Human Reproduction 2008; 23(7): 1594–1601.
9. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113-116.
10. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in non obese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57: 356-359.
11. Dunaif A, Finegood DT. β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:942-947.
12. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83:2694-2698.
13. Hemati T, Moghadami-Tabrizi N, DavariTanha F, Salmanian B, Javadian P. High plasma homocysteine and insulin resistance in patients with polycystic ovarian syndrome. Iranian Journal of Reproductive Medicine 2011; 9 :223-228.
14. Olivier V, Regine P, Steegers-Theunissen M, Huberdina P, Smedts M, Geesje M. A more atherogenic serum Lipoprotein profile is present in women with polycystic ovary syndrome: A case-control study. J Clin Endocrinol Metab 2008;93(2):470-476.
15. Anuradha K, Sreekumari N, Lavanya R. Association of obesity and Insulin resistance with dyslipidemia in Indian women with polycystic ovary syndrome. Ind J Med Scien 2006;60;11:447-453.
16. Mirjana. S, Milos Z, Jasmina C. Insulin levels and lipid profile in lean women with polycystic ovary syndrome. Abstracts 2007;14:649.
17. Haffner SM, Valdez RA, Hazude HP, Mitchel BD, Morales PA, Stern MP et al. Prospective analysis of the insulin-resistance syndrome (syndrome x). Diabetes 1992;41:715.
18. Robinson S, Henderson AD, Gelding SV, et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovary syndrome. Clin Endocrinol 1996;44:277–84.
19. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos P. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007;18:280-285.
20. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochem Biophys Acta 1997;1345:136-150.
21. Dejager S, Pichard C, Giral P, et al. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf) 2001;54:455-462.
22. Polderman KH, Gooren JG, Asscherman H. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994;79:265-271.
23. Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (oxf) 2003;58:562-571
24. Hanratty CG, McGrath LT, McAuley DF, Young IS, Johnston GD. The effects of oral methionine and homocysteine on endothelial function. Heart 2001; 85(3):326-30.
25. Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, Oto A.Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76(3): 511-6.
26. Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002;53(3): 157-62.
27. Morey Schachter, Arieh Raziel, Shevach Friedler, Deborah Strassburger, Orna Bern and Raphael Ron-El, Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Human Reproduction 2003; 18(4):721-727.
28. Ilhan Tarkun, Berrin Cetinarslan Zeynep, Canturk Erdem Turemen. The Plasma Homocysteine Concentrations and Relationship with Insulin Resistance in Young Women with Polycystic Ovary Syndrome Turkish. Journal of Endocrinology and Metabolism 2005; 1: 23-28.
29. Mujumdar, V.S., Tummalapalli, C.M., Aru, G.M. and Tyagi, S.C. Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR. Am. J. Physiol 2002;282:1009-10015.
30. Zhang, C., Yong, C., Adachi, M.T., Oshiro, S., Aso, T., Kaufman, R.J. and Kitajima, S. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J. Biol. Chem 2001;276:35867- 35874.
31. Laivuori, H., Kaaja, R., Turpeinen, U., Viinikka, L. and Ylikorkala, O. Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia. Obstet. Gynecol 1999;93:489-493.
32. Tsanadis, G., Vartholomatos, G., Korkontzelos, I., Avgoustatos, F., Kakosimos, G., Sotiriadis, A., Tatsoni, A., Eleftheriou, A. and Lolis, D. Polycystic ovarian syndrome and thrombophilia. Hum. Reprod 2002; 17: 314-319.
33. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.N Engl J Med 2000; 342: 836-843.
34. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003; 108: 2054-2059.
35. Freeman DJ, Norrie J, Caslake MJ, et al. West of Scotland Coronary Prevention Study, C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-1600.
36. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, and Blumenfeld Z. Increased C - reactive protein Levels in the Polycystic Ovary Syndrome: A Marker of Cardiovascular Disease. Journal of Clinical Endocrinology and Metabolism 2004; 89(5):2160–2165.
37. Talbott EO, Zborowski JV, Boudreaux MY, Mchugh-pemu KP, Sutton- tyrrell K, Guzick D.S. The Relationship between C - reactive protein and Carotid Intima-Media Wall Thickness in Middle-Aged Women with Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology and Metabolism 2004; 89(12):6061–6067.
38. Alain Tedgui. The role of inflammation in atherothrombosis: implications for clinical practice. Vascular Medicine 2005; 10: 45–53.
39. Ridker PM, Buring JE, Cook NR, Rifai N. Creactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8- year follow-up of 14719 initially healthy American women. Circulation 2003; 107:391–397.
40. Anttila L, Rouru J, Penttil T, and. Irjala K. Normal serum uric acid concentrations in women with polycystic ovary syndrome. Human Reproduction 1996; 11: 2405-2407.